Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 03, 2015 2:16 PM ET

Pharmaceuticals

Company Overview of Noven Pharmaceuticals, Inc.

Company Overview

Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and estradiol transdermal system for the prevention of postmenopausal osteoporosis. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in ...

11960 SW 144th Street

Miami, FL 33186

United States

Founded in 1987

610 Employees

Phone:

305-253-5099

Fax:

305-251-1887

Key Executives for Noven Pharmaceuticals, Inc.

Chief Executive Officer and President
Age: 49
Chief Financial Officer, Principal Accounting Officer and Vice President
Age: 57
Vice President of Operations
Chief Scientific Officer and Vice President
Age: 59
Chief Medical Officer and Executive Vice President of Product Development
Age: 60
Compensation as of Fiscal Year 2015.

Noven Pharmaceuticals, Inc. Key Developments

Noven Pharmaceuticals, Inc. Replaces Andrew Panagy with Scott Briggs as Vice President, Marketing & Sales

Noven Pharmaceuticals, Inc. announced the appointment of Scott Briggs as the company’s new Vice President, Marketing & Sales, succeeding Andrew Panagy, who is retiring. In this role, reporting to Jeffrey Eisenberg, the company’s President and Chief Executive Officer, Briggs is responsible for all marketing and sales activities at Noven and Noven Therapeutics (the company’s specialty pharmaceutical business unit). Prior to this appointment, he served as Vice President Women’s Health Sales for Noven Therapeutics, and as Noven’s Executive Director, Marketing and Managed Markets.

Noven Pharmaceuticals, Inc. Announces New 0.025 Mg/Day Dosage Strength for Minivelle

Noven Pharmaceuticals, Inc. announced that the new 0.025 mg/day dosage strength for Minivelle® (estradiol transdermal system) is now available by prescription nationwide for only the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. In September 2014, the FDA approved a new indication for prevention of postmenopausal osteoporosis for all doses of Minivelle. The new 0.025 mg/day low dose was approved for this indication only. The new 0.025 mg/day patch is 33% smaller than Minivelle 0.0375 mg/day, already about the size of a dime, making the 0.025 mg/day patch the world's smallest estrogen therapy patch ever. Minivelle is now available with five dosing options – 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, with the newly available lower dose of 0.025 mg/day indicated for the prevention of postmenopausal osteoporosis only. The higher doses are indicated to treat moderate to severe VMS as well. If a patient uses Minivelle only to prevent osteoporosis from menopause, they should talk with their healthcare provider about whether a different treatment or medicine without estrogens might be better for them. Noven offers a savings program to help reduce Minivelle co-pays for eligible patients. On co-pays up to $70, patients pay no more than $15 for a one-month supply. On co-pays in excess of $70, patients may qualify for up to $55 in savings for a one-month supply. Patients can take advantage of this offer each month, for up to 12 uses.

Noven Receives FDA Approval of New Indication with New Dose for Minivelle(R) (Estradiol Transdermal System)

Noven Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. With this new approval, women who are using Minivelle to treat their VMS symptoms have the benefit of also helping to prevent osteoporosis. The new 0.025 mg/day patch is 33% smaller than Minivelle 0.0375 mg/day that is already only about the size of a dime, the planet's smallest estrogen therapy patch ever. Minivelle is now approved with five dosing options -- 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, with the newly approved, lower dose of 0.025 mg/day indicated for the prevention of postmenopausal osteoporosis only. If a patient uses Minivelle only to prevent osteoporosis from menopause, they should talk with their healthcare provider about whether a different treatment or medicine without estrogens might be better for them. The new lower dose of 0.025 mg/day is expected to be available in pharmacies in January 2015. Noven offers a savings program to help reduce the Minivelle co-pay for eligible patients. Eligible patients pay no more than $15 each month for up to 12 uses on their Minivelle prescriptions.

Similar Private Companies By Industry

Company Name Region
Jenken Biosciences, Inc. United States
FSC Laboratories, Inc. United States
Atrium Biotech Investments, Inc. United States
ILEX Pharmaceuticals, L.P United States
Midwest BioResearch LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Noven Pharmaceuticals, Inc., please visit www.noven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.